Richard Hester, MD
Family Medicine · Poplar Bluff, MONPI 1831280197
Payments from drug & device makers
Across 189 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$599
- Lilly USA, LLC$200
- AstraZeneca$193
- Novo Nordisk$184
- Otsuka America Pharmaceutical, Inc.$145
- AbbVie$142
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,734100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 51 | $599 |
| Lilly USA, LLC | 14 | $200 |
| AstraZeneca | 14 | $193 |
| Novo Nordisk | 12 | $184 |
| Otsuka America Pharmaceutical, Inc. | 10 | $145 |
| AbbVie | 7 | $142 |
| Johnson & Johnson | 8 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $122 |
| Amgen | 5 | $104 |
| Amarin Pharma, Inc. | 7 | $101 |
| Boehringer Ingelheim | 6 | $87 |
| Eisai Inc. | 6 | $87 |
| Sunovion Pharmaceuticals Inc. | 7 | $78 |
| Pfizer | 5 | $75 |
| Merck | 4 | $60 |
| Grifols USA, LLC | 3 | $55 |
| Novartis | 3 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Abbott | 2 | $32 |
| Sanofi | 1 | $28 |
| Organon | 2 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,734 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 150 | $171,776 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 215 | $166,673 |
| EliquisApixaban | 129 | $107,995 |
| TrulicityDulaglutide | 91 | $92,625 |
| JardianceEmpagliflozin | 92 | $84,308 |
| MounjaroTirzepatide | 66 | $72,699 |
| XareltoRivaroxaban | 67 | $55,556 |
| FarxigaDapagliflozin Propanediol | 55 | $51,243 |
| LinzessLinaclotide | 72 | $50,473 |
| JanuviaSitagliptin Phosphate | 57 | $41,835 |
| VascepaIcosapent Ethyl | 93 | $38,138 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $36,248 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $34,622 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 63 | $30,954 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $29,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $599 | $222,713323 claims |
| Novo NordiskOzempic | $184 | $171,776150 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $200 | $165,323157 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat | $87 | $143,116200 claims |
| PfizerEliquis, Nurtec Odt | $75 | $132,869146 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $193 | $115,353186 claims |
| AbbVieLinzess, Restasis, Savella, Creon | $142 | $83,072134 claims |
| Johnson & JohnsonXarelto | $131 | $55,55667 claims |
| MerckJanuvia | $60 | $41,83557 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $18,90331 claims |
| NovartisEntresto | $55 | $16,67412 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $122 | $6,73912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Poplar Bluff
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.